Screener
iRadimed IRMD Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Provision for income tax expense | 1,951 | 1,258 |
| Net income | $5,818 | $4,687 |
| Net income per share: | ||
| Basic | $0.46 | $0.37 |
| Diluted | $0.45 | $0.37 |
| Weighted average shares outstanding: | ||
| Basic | 12,783 | 12,714 |
| Diluted | 12,870 | 12,826 |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's shares (diluted)?
- iRadimed (IRMD) reported shares (diluted) of 12.9M in Q1 2026.
- How has iRadimed's shares (diluted) changed year-over-year?
- iRadimed's shares (diluted) increased by 0.3% year-over-year, from 12.8M to 12.9M.
- What is the long-term trend for iRadimed's shares (diluted)?
- Over 4 years (2021 to 2025), iRadimed's shares (diluted) has grown at a 0.5% compound annual growth rate (CAGR), from 50.3M to 51.4M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about iRadimed's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude